Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Treating Advanced Solid Tumors in People with Inherited PTEN Mutations Using the Investigational Drug TAS-117
Glossary on
off
Printer Friendly Page Treating Advanced Solid Tumors in People with Inherited PTEN Mutations Using the Investigational Drug TAS-117

Treating Advanced Solid Tumors in People with Inherited PTEN Mutations Using the Investigational Drug TAS-117

Clinicaltrials.gov identifier:
NCT04770246


People with advanced cancer and an inherited PTEN mutation

Study Contact Information:

For additional information, please contact:

Osamu Takahashi, MD, PhD by phone: 609-250-7336 or by email at: [email protected]

Treating Advanced Solid Tumors in People with Inherited PTEN Mutations Using the Investigational Drug TAS-117

About the Study

This study will look at how well the TAS-117 works for treating people with an inherited mutation and advanced or solid tumors (excluding primary brain tumors). NOTE: this study is no longer enrolling people. 

This Study is Open To:

NOTE: this study is no longer enrolling people. 

This Study is Not Open To:

NOTE: this study is no longer enrolling people.